Photosensitizers as virucidal agents

Area of Science:

• Photodynamic therapy
• Virology
• Blood product safety

Background:

• Enveloped viruses, such as HIV, pose a significant risk in blood transfusions.
• Benzoporphyrin derivative monoacid ring A (BPD-MA) is a photosensitizer investigated for antiviral applications.
• The absorption maximum of BPD-MA at 690 nm is suitable for activation within blood components.

Purpose of the Study:

• To evaluate the efficacy of BPD-MA and light in eliminating human immunodeficiency virus (HIV) from infected blood.
• To determine if BPD-MA phototherapy damages blood cells or components.
• To elucidate the mechanism of selective viral inactivation in HIV-infected blood.

Main Methods:

• Treatment of HIV-infected whole blood with BPD-MA and light (690 nm).
• Culturing treated blood and testing for viral p24 antigen to assess viral load.
• Flow cytometry analysis to identify targeted cell populations based on surface markers.
• Investigating the expression of interleukin 2 receptor and DR antigen on infected cells.

Main Results:

• BPD-MA and light effectively reduced HIV levels in treated blood cultures.
• No significant damage to red blood cells or other blood components was observed.
• Flow cytometry revealed selective destruction of white blood cells expressing the interleukin 2 receptor and DR antigen.
• These targeted cells are activated lymphocytes, which are known to harbor HIV.

Conclusions:

• BPD-MA phototherapy is a potential method for inactivating HIV in blood products.
• The selective targeting of activated CD4+ T cells explains the efficacy against intracellular HIV.
• This approach offers a promising strategy for enhancing blood safety by reducing transfusion-transmitted infections.